Videos

ImprimisRx President John Saharek shares an update on a few of the company's latest products during AAO 2021.

Ajay Kuriyan, MD, discusses fluctuations in central subfield thickness associated with worse visual outcomes in patients with diabetic macular edema in clinical trial setting.

Peter J. McDonnell, MD, speaks on what attendees can look forward to at this year’s 2021 annual American Academy of Ophthalmology meeting in New Orleans.

Bausch + Lomb's Yolande Barnard, shares an update on the FDA approval of XIPERE for the treatment of macular edema associated with uveitis.

Michael Rivers, MD, director of ophthalmology, Modernizing Medicine, shares what lingers on his mind in the field of ophthalmology at the end of the day.

JD Schaub, chief operating officer at RVL Pharmaceuticals, shares what lingers on his mind in the ophthalmic field at the end of the day.

In honor of World Sight Day, staff from our parent company, MJH Life Sciences, share their perspectives on the significance of vision in their lives.

Ophthalmologists and industry executives share what lingers on their minds at the end of the day.

Justis P. Ehlers, MD, speaks on the findings from a higher-order OCT analysis for inflammatory signal biomarkers in the HAWK Study.

Alcon's Paul Hallen offers a look at the highlights from the 2021 ASRS annual meeting's OIS panel as well as the company's latest innovations.

Caroline Baumal, MD, highlights results from the Phase 3 YOSEMITE and RHINE trials, providing an overview of the efficacy, safety and durability of faricimab in DME.

Ophthalmologists and industry executives share what lingers on their minds at the end of the day.

Robert Weinstock, MD, discusses the efficacy and safety of intracameral dexamethasone suspension 9% compared to standard of care topical regimen for eyes receiving cataract surgery.

Cathleen McCabe, MD, shares an overview of results from a retrospective study highlighting the effectiveness of dexamethasone intraocular suspension 9% following cataract surgery.

Tibor Juhasz, CEO of ViaLase, Inc, discusses the company's development of a novel, noninvasive high-resolution OCT image-guided femtosecond laser technology for the treatment of open-angle glaucoma.

Lisa Nijm, MD, JD, discusses the brand-new Real World Ophthalmology conference, designed to support ophthalmologists starting practice.

Tunde Peto, MD, offers advice on how to create the best virtual environment for patients diagnosed with diabetic eye disease.

Grazia Pertile, MD, discusses the highlights of her presentations on the management of retinal folds after retinal detachment and the role of the anterior vitreous as a cause of recurrent retinal detachment.

Javier Zarranz-Ventura MD, PhD, FEBO, discusses the key highlights from his presentation on a clinical investigation of suitable naïve versus pre-treated DME patients, and what it means for future research.

Carel B. Hoyng, MD, discusses his presenation regarding macula dystrophies, including Stargardt disease, Best disease, X-linked retinoschisis, and the peripherin-2 (PRPH2) gene.

Quan Dong Nguyen, MD, MSc, FARVO, FASRS, highlights his presentation regarding new biological treatments of posterior uveitis.

Ramin Tadayoni, MD, PhD, discusses the pathology of myopia around the globe.

Jennifer Sun, MD, MPH, explores the question of whether ophthalmologists should be using anti-VEGF agents to treat patients with nonproliferative diabetic retinopathy (NPDR).

George O. Waring IV, MD, FACS, discusses the latest results from the GEMINI 1 clinical trial of AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia.

Steven Greenstein, MD, reports on the 10-year postop data from an epi-off corneal collagen cross-linking treatment in keratoconus and ectasia patients.

COO JD Schaub provides an overview of how RVL Pharmaceuticals has shifted toward becoming an ocular aesthetics company, with the sole purpose to fully focus on UPNEEQ®.

This program is sponsored by Eyevance Pharmaceuticals, a Santen company.